GGrantIndex
← Leaderboards

David Daniels

Mayo Clinic Rochester

$4,078,623
Attributed
$4,078,623
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY201724
$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$4,078,623 · 4

By mechanism

R01$1,838,354 · 1
K08$908,385 · 1
R61$899,750 · 1
R33$432,134 · 1

Top collaborators

No co-investigators on record.

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Methionine

Research focus

MethionineNovel TherapeuticsMalignant NeoplasmsHistone H3Neoplastic CellMutationLysineChildDiagnosisDiffuse Intrinsic Pontine GliomaMethylation PatternEpigenetic ProcessGene ExpressionChildhood GliomaAffectCellsBrainBrain NeoplasmsCessation Of LifeClinical TrialsCancer CellCell LineGenesPathologic

Grant awards (12)

Development of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation$432,134
R33 · FY2024 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$362,372
R01 · FY2024 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$373,578
R01 · FY2023 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$373,578
R01 · FY2022 · NS · contact PI
Deve inlopment of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation$899,750
R61 · FY2021 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$358,194
R01 · FY2021 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$177,821
K08 · FY2021 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$370,632
R01 · FY2020 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$183,141
K08 · FY2020 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$183,141
K08 · FY2019 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$182,141
K08 · FY2018 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$182,141
K08 · FY2017 · NS · contact PI